SIR2501 for Peripheral Neuropathy
What You Need to Know Before You Apply
What is the purpose of this trial?
This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).
Are You a Good Fit for This Trial?
This trial is for adults with solid tumors who are about to start paclitaxel-based chemotherapy. Participants should be generally healthy aside from their cancer and able to follow study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
SIR2501 is administered to patients receiving paclitaxel-based chemotherapy to evaluate safety, tolerability, and pharmacokinetics
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of treatment-emergent adverse events and neuropathy
What Are the Treatments Tested in This Trial?
Interventions
- SIR2501
Trial Overview
The study tests SIR2501, given alongside standard paclitaxel chemotherapy, to see if it is safe and can help prevent or reduce nerve damage (peripheral neuropathy) caused by the chemo.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sironax USA, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.